{"id":745369,"date":"2016-06-06T07:00:00","date_gmt":"2016-06-06T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\/"},"modified":"2025-11-07T01:25:47","modified_gmt":"2025-11-07T06:25:47","slug":"keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\/","title":{"rendered":"KEYTRUDA\u00ae (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087"},"content":{"rendered":"<p class=\"bwalignc\">       Findings Support Initiation of Phase 3 Pivotal Study (KEYNOTE-204)        Evaluating KEYTRUDA Versus Brentuximab Vedotin in Relapsed or Refractory        cHL     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the first-time presentation of findings from<br \/>\n      KEYNOTE-087, the phase 2 study investigating the use of KEYTRUDA<sup>\u00ae <\/sup>(pembrolizumab),<br \/>\n      the company\u2019s anti-PD-1 therapy, as a monotherapy in patients with<br \/>\n      relapsed or refractory classical Hodgkin lymphoma (cHL). These data will<br \/>\n      be presented today at the 52<sup>nd<\/sup> Annual Meeting of the American<br \/>\n      Society of Clinical Oncology (ASCO) in Chicago from 8:00 \u2013 11:30 a.m.<br \/>\n      CDT (Location: Hall A) and in a poster discussion from 1:15 \u2013 2:45 p.m.<br \/>\n      CDT (Location: E354b) (Abstract #7555).\n    <\/p>\n<p>\n      Results included an analysis of outcome measurements from the study\u2019s<br \/>\n      three patient cohorts: patients whose disease progressed following an<br \/>\n      autologous stem cell transplantation and subsequent treatment with<br \/>\n      brentuximab vedotin, an antibody drug conjugate (Cohort 1); patients who<br \/>\n      failed salvage chemotherapy and were ineligible for a transplant and<br \/>\n      whose disease progressed following treatment with brentuximab vedotin<br \/>\n      (Cohort 2); and patients whose disease progressed after transplant and<br \/>\n      who did not receive brentuximab vedotin after transplant (Cohort 3).<br \/>\n      Data showed that the overall response rate (ORR) was more than 70<br \/>\n      percent across all three cohorts with the highest ORR, at 83 percent,<br \/>\n      observed in Cohort 2. Results also included an analysis of patients with<br \/>\n      primary refractory disease, defined as failure to achieve complete or<br \/>\n      partial response to first-line treatment. In this patient population,<br \/>\n      the ORR (by investigator review) was 78 percent. Additionally, 90 to 93<br \/>\n      percent of patients experienced a reduction in tumor size across all<br \/>\n      three cohorts.\n    <\/p>\n<p>\n      \u201cRecurrence of Hodgkin lymphoma occurs in almost half of patients<br \/>\n      following autologous stem cell transplantation, and the prognosis for<br \/>\n      patients relapsing or refractory to second-line chemotherapy and<br \/>\n      transplant is particularly poor, which means there is a significant need<br \/>\n      to identify therapeutic options that provide meaningful clinical<br \/>\n      benefit,\u201d said Dr. Craig Moskowitz, clinical director, division of<br \/>\n      hematologic oncology, Memorial Sloan Kettering Cancer Center. \u201cThese<br \/>\n      early data are encouraging, as they demonstrate high response rates \u2013 up<br \/>\n      to 83 percent \u2013 with pembrolizumab in heavily pre-treated patients.\u201d\n    <\/p>\n<p>\n      Data from KEYNOTE-087 supported the recent Breakthrough Therapy<br \/>\n      Designation granted to KEYTRUDA (pembrolizumab) by the U.S. Food and<br \/>\n      Drug Administration (FDA) for this type of blood cancer. Additionally,<br \/>\n      findings from this study support the continued development of KEYTRUDA<br \/>\n      in patients with cHL, including a phase 3 registration-enabling study<br \/>\n      (KEYNOTE-204) designed to evaluate monotherapy KEYTRUDA versus<br \/>\n      brentuximab vedotin in patients with relapsed or refractory cHL.\n    <\/p>\n<p>\n      \u201cOur extensive clinical development program is studying KEYTRUDA in a<br \/>\n      broad range of solid and blood cancers \u2013 including classical Hodgkin<br \/>\n      lymphoma, where there remains a significant unmet need for patients who<br \/>\n      do not respond to or relapse following initial treatment,\u201d said Dr.<br \/>\n      Roger Dansey, senior vice president and therapeutic area head, oncology<br \/>\n      late-stage development, Merck Research Laboratories. \u201cThese exciting<br \/>\n      data from KEYNOTE-087 reinforce the potential of KEYTRUDA in hematologic<br \/>\n      cancers and further invigorate our commitment to improving outcomes<br \/>\n      across a variety of blood cancers.\u201d\n    <\/p>\n<p>\n      Results presented at ASCO were based on an analysis of 90 patients<br \/>\n      across three study cohorts. These data showed (per investigator review):\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        In Cohort 1 (progressed after transplant and subsequent brentuximab<br \/>\n        vedotin treatment; n=30), ORR was 73 percent (95% CI, 54-88) \u2013 with<br \/>\n        complete responses in 27 percent (95% CI, 12-46) and partial responses<br \/>\n        in 47 percent (95% CI, 28-66) of patients. Seventeen percent of<br \/>\n        patients had stable disease (95% CI, 6-35) and 10 percent of patients<br \/>\n        had progressive disease (95% CI, 2-27).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In Cohort 2 (progressed following salvage chemotherapy,<br \/>\n        transplant-ineligible, and progressed following brentuximab vedotin<br \/>\n        treatment; n=30), ORR was 83 percent (95% CI, 65-94) \u2013 with complete<br \/>\n        responses in 30 percent (95% CI, 15-49) and partial responses in 53<br \/>\n        percent (95% CI, 34-72) of patients. Seven percent of patients had<br \/>\n        stable disease (95% CI, 1-22) and 7 percent of patients had<br \/>\n        progressive disease (95% CI, 1-22).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In Cohort 3 (progressed after transplant and not treated with<br \/>\n        brentuximab vedotin after transplant; n=30), ORR was 73 percent (95%<br \/>\n        CI, 54-88) \u2013 with complete responses in 30 percent (95% CI, 15-49) and<br \/>\n        partial responses in 43 percent of patients (95% CI, 26-63). Thirteen<br \/>\n        percent of patients had stable disease (95% CI, 4-31) and 13 percent<br \/>\n        of patients had progressive disease (95% CI, 4-31).\n      <\/li>\n<\/ul>\n<p>\n      In patients with primary refractory disease (n=37), ORR was 78 percent<br \/>\n      (95% CI, 62-90) \u2013 with complete responses in 35 percent (95% CI, 20-53)<br \/>\n      and partial responses in 43 percent (95% CI, 27-61) of patients. Eleven<br \/>\n      percent of patients had stable disease (95% CI, 3-25) and 8 percent of<br \/>\n      patients had progressive disease (95% CI, 2-22).\n    <\/p>\n<p>\n      The safety profile of KEYTRUDA (pembrolizumab) was consistent with that<br \/>\n      observed in previously reported studies. Grade 3-4 treatment-related<br \/>\n      adverse events were observed in 4 percent of patients and included<br \/>\n      neutropenia (n=1), increased amylase (n=1), cytokine release syndrome<br \/>\n      (n=1), herpes zoster (n=1), increased lipase (n=1), lichenoid dermatosis<br \/>\n      (n=1), colitis (n=1), and diarrhea (n=1). Two patients discontinued due<br \/>\n      to treatment-related adverse events (Grade 2 infusion-related reaction<br \/>\n      and Grade 2 pneumonitis; both Cohort 2). The immune-mediated adverse<br \/>\n      events (any grade) were rash (n=4, all Grade 1), pneumonitis (n=2, both<br \/>\n      Grade 2), and colitis (n=1, Grade 3). There were no treatment-related<br \/>\n      deaths.\n    <\/p>\n<p>\n      The KEYTRUDA clinical development program includes more than 30 tumor<br \/>\n      types in more than 270 clinical trials, including more than 100 trials<br \/>\n      that combine KEYTRUDA with other cancer treatments. For hematologic<br \/>\n      malignancies specifically, Merck is conducting a broad immuno-oncology<br \/>\n      clinical development program. To date, the program is assessing the role<br \/>\n      of monotherapy and combination regimens with KEYTRUDA across a variety<br \/>\n      of hematologic malignancies including leukemia, lymphomas, and myeloma,<br \/>\n      and includes five registration-enabling studies.\n    <\/p>\n<p>\n      <b>About KEYNOTE-087<\/b>\n    <\/p>\n<p>\n      KEYNOTE-087 is a multicenter, open-label, multi-cohort,<br \/>\n      activity-estimating phase 2 trial evaluating KEYTRUDA (200 mg fixed dose<br \/>\n      every three weeks) monotherapy in patients with relapsed or refractory<br \/>\n      cHL across three cohorts. The primary endpoints include overall safety,<br \/>\n      tolerability, and ORR (per central review); secondary endpoints include<br \/>\n      ORR (per investigator review), progression-free survival (PFS), and<br \/>\n      overall survival (OS). The patient cohorts are intended to assess the<br \/>\n      outcome measures in patients whose disease progressed following an<br \/>\n      autologous stem cell transplantation and subsequent treatment with<br \/>\n      brentuximab vedotin, an antibody drug conjugate (Cohort 1); patients who<br \/>\n      failed salvage chemotherapy and were ineligible for a transplant and<br \/>\n      whose disease progressed following treatment with brentuximab vedotin<br \/>\n      (Cohort 2); and patients whose disease progressed after transplant and<br \/>\n      who did not receive brentuximab vedotin after transplant (Cohort 3).\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<br \/>\n      100 mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with metastatic<br \/>\n      non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as<br \/>\n      determined by an FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. An improvement in survival or<br \/>\n      disease-related symptoms has not yet been established. Continued<br \/>\n      approval for this indication may be contingent upon verification and<br \/>\n      description of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      KEYTRUDA is administered at a dose of 2 mg\/kg as an intravenous infusion<br \/>\n      over 30 minutes every three weeks for the approved indications.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b>&nbsp;(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Immune-mediated pneumonitis, including fatal cases, occurred in patients<br \/>\n      receiving KEYTRUDA. Pneumonitis occurred in 32 (2.0%) of 1567 patients<br \/>\n      with melanoma, including Grade 1 (0.8%), 2 (0.8%), and 3 (0.4%)<br \/>\n      pneumonitis. Pneumonitis occurred in 19 (3.5%) of 550 patients with<br \/>\n      NSCLC, including Grade 2 (1.1%), 3 (1.3%), 4 (0.4%), or 5 (0.2%)<br \/>\n      pneumonitis and more frequently in patients with a history of<br \/>\n      asthma\/chronic obstructive pulmonary disease (5.4%) or prior thoracic<br \/>\n      radiation (6.0%). Monitor patients for signs and symptoms of<br \/>\n      pneumonitis. Evaluate suspected pneumonitis with radiographic imaging.<br \/>\n      Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold<br \/>\n      KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      Immune-mediated colitis occurred in 31 (2%) of 1567 patients with<br \/>\n      melanoma, including Grade 2 (0.5%), 3 (1.1%), and 4 (0.1%) colitis.<br \/>\n      Immune-mediated colitis occurred in 4 (0.7%) of 550 patients with NSCLC,<br \/>\n      including Grade 2 (0.2%) or 3 (0.4%) colitis. Monitor patients for signs<br \/>\n      and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA (pembrolizumab) for Grade 2 or 3;<br \/>\n      permanently discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Immune-mediated hepatitis occurred in patients receiving KEYTRUDA.<br \/>\n      Hepatitis occurred in 16 (1%) of 1567 patients with melanoma, including<br \/>\n      Grade 2 (0.1%), 3 (0.7%), and 4 (0.1%) hepatitis. Monitor patients for<br \/>\n      changes in liver function. Administer corticosteroids for Grade 2 or<br \/>\n      greater hepatitis and, based on severity of liver enzyme elevations,<br \/>\n      withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 13 (0.8%) of 1567 patients with melanoma,<br \/>\n      including Grade 2 (0.3%), 3 (0.3%), and 4 (0.1%) hypophysitis.<br \/>\n      Hypophysitis occurred in 1 (0.2 %) of 550 patients with NSCLC, which was<br \/>\n      Grade 3 in severity. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 51 (3.3%) of 1567 patients with melanoma,<br \/>\n      including Grade 2 (0.6%) and 3 (0.1%) hyperthyroidism. Hypothyroidism<br \/>\n      occurred in 127 (8.1%) of 1567 patients with melanoma, including Grade 3<br \/>\n      (0.1%) hypothyroidism. Hyperthyroidism occurred in 10 (1.8%) of 550<br \/>\n      patients with NSCLC, including Grade 2 (0.7%) or 3 (0.3%)<br \/>\n      hyperthyroidism. Hypothyroidism occurred in 38 (6.9%) of 550 patients<br \/>\n      with NSCLC, including Grade 2 (5.5%) or 3 (0.2%) hypothyroidism. Thyroid<br \/>\n      disorders can occur at any time during treatment. Monitor patients for<br \/>\n      changes in thyroid function (at the start of treatment, periodically<br \/>\n      during treatment, and as indicated based on clinical evaluation) and for<br \/>\n      clinical signs and symptoms of thyroid disorders. Administer replacement<br \/>\n      hormones for hypothyroidism and manage hyperthyroidism with thionamides<br \/>\n      and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 3<br \/>\n      (0.1%) of 2117 patients. Monitor patients for hyperglycemia or other<br \/>\n      signs and symptoms of diabetes. Administer insulin for type 1 diabetes,<br \/>\n      and withhold KEYTRUDA and administer anti-hyperglycemics in patients<br \/>\n      with severe hyperglycemia.\n    <\/p>\n<p>\n      Immune-mediated nephritis occurred in patients receiving KEYTRUDA.<br \/>\n      Nephritis occurred in 7 (0.4%) of 1567 patients with melanoma including,<br \/>\n      Grade 2 (0.2%), 3 (0.2%), and 4 (0.1%) nephritis. Monitor patients for<br \/>\n      changes in renal function. Administer corticosteroids for Grade 2 or<br \/>\n      greater nephritis. Withhold KEYTRUDA (pembrolizumab) for Grade 2;<br \/>\n      permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 1567 patients<br \/>\n      with melanoma: arthritis (1.6%), exfoliative dermatitis, bullous<br \/>\n      pemphigoid, uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. The<br \/>\n      following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of 550 patients with NSCLC: rash, vasculitis,<br \/>\n      hemolytic anemia, serum sickness, and myasthenia gravis.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In Trial 6, KEYTRUDA was discontinued due to adverse reactions in 9% of<br \/>\n      555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions with KEYTRUDA (pembrolizumab)<br \/>\n      vs ipilimumab were fatigue (28% vs 28%), diarrhea (26% with KEYTRUDA),<br \/>\n      rash (24% vs 23%), and nausea (21% with KEYTRUDA). Corresponding<br \/>\n      incidence rates are listed for ipilimumab only for those adverse<br \/>\n      reactions that occurred at the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      In Trial 2, KEYTRUDA was discontinued due to adverse reactions in 12% of<br \/>\n      357 patients with advanced melanoma; the most common (\u22651%) were general<br \/>\n      physical health deterioration (1%), asthenia (1%), dyspnea (1%),<br \/>\n      pneumonitis (1%), and generalized edema (1%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 14% of patients; the most common<br \/>\n      (\u22651%) were dyspnea (1%), diarrhea (1%), and maculo-papular rash (1%).<br \/>\n      The most common adverse reactions with KEYTRUDA vs chemotherapy were<br \/>\n      fatigue (43% with KEYTRUDA), pruritus (28% vs 8%), rash (24% vs 8%),<br \/>\n      constipation (22% vs 20%), nausea (22% with KEYTRUDA), diarrhea (20% vs<br \/>\n      20%), and decreased appetite (20% with KEYTRUDA). Corresponding<br \/>\n      incidence rates are listed for chemotherapy only for those adverse<br \/>\n      reactions that occurred at the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 14% of 550<br \/>\n      patients with NSCLC. Serious adverse reactions occurred in 38% of<br \/>\n      patients. The most frequent serious adverse reactions reported at least<br \/>\n      2% of patients were pleural effusion, pneumonia, dyspnea, pulmonary<br \/>\n      embolism, and pneumonitis. The most common adverse reactions (reported<br \/>\n      in at least 20% of patients) were fatigue (44%), cough (29%), decreased<br \/>\n      appetite (25%), and dyspnea (23%).\n    <\/p>\n<p>\n      No formal pharmacokinetic drug interaction studies have been conducted<br \/>\n      with KEYTRUDA.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 270 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51356238&amp;newsitemid=20160606005499&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=62a47fd6ddd4a52aa567b1c0780f2d18\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51356238&amp;newsitemid=20160606005499&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=72a632e99829ecc37e5fce302dd7ca83\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51356238&amp;newsitemid=20160606005499&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=61ea285f241c0f093a2f5d190e544802\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51356238&amp;newsitemid=20160606005499&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=21460dabeb738a756feeb6c312e56d0f\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51356238&amp;newsitemid=20160606005499&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=583a6bd8c45276834b52d46b71c8b697\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51356238&amp;newsitemid=20160606005499&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=17b822c552058d7a784261da9a577d65\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful.&nbsp;If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51356238&amp;newsitemid=20160606005499&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=54074451d98205f7c50dace6aa291f2f\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51356238&amp;newsitemid=20160606005499&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=d78249d467038f1fbc8a1a048067643f\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<br \/>\n      Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51356238&amp;newsitemid=20160606005499&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=1a34abc8a9aca78c5e4404134fed07dd\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160606005499r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>An Phan,        908-255-6325<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>or<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings from KEYNOTE-087, the phase 2 study investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as a monotherapy in patients with relapsed or refractory classical Hodgkin lymphoma (cHL). These data will be presented today at the 52 nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 8:00 \u2013 11:30 a.m. CDT (Location: Hall A) and in a poster discussion from 1:15 \u2013 2:45 p.m. CDT (Location: E354b) (Abstract #7555). Results included an analysis of outcome measurements from the study\u2019s three patient cohorts: patients whose disease progressed following an autologous stem cell transplantation and subsequent treatment with brentuximab vedotin, an antibody drug conjugate (Cohort 1); patients who failed salvage chemotherapy and were ineligible for a transplant and whose disease progressed following treatment with<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289,56],"class_list":["post-745369","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KEYTRUDA\u00ae (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KEYTRUDA\u00ae (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings from KEYNOTE-087, the phase 2 study investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as a monotherapy in patients with relapsed or refractory classical Hodgkin lymphoma (cHL). These data will be presented today at the 52 nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 8:00 \u2013 11:30 a.m. CDT (Location: Hall A) and in a poster discussion from 1:15 \u2013 2:45 p.m. CDT (Location: E354b) (Abstract #7555). Results included an analysis of outcome measurements from the study\u2019s three patient cohorts: patients whose disease progressed following an autologous stem cell transplantation and subsequent treatment with brentuximab vedotin, an antibody drug conjugate (Cohort 1); patients who failed salvage chemotherapy and were ineligible for a transplant and whose disease progressed following treatment with\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\\\/\",\"name\":\"KEYTRUDA\u00ae (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-06-06T07:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KEYTRUDA\u00ae (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KEYTRUDA\u00ae (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\/","og_locale":"en_US","og_type":"article","og_title":"KEYTRUDA\u00ae (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087 - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings from KEYNOTE-087, the phase 2 study investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as a monotherapy in patients with relapsed or refractory classical Hodgkin lymphoma (cHL). These data will be presented today at the 52 nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 8:00 \u2013 11:30 a.m. CDT (Location: Hall A) and in a poster discussion from 1:15 \u2013 2:45 p.m. CDT (Location: E354b) (Abstract #7555). Results included an analysis of outcome measurements from the study\u2019s three patient cohorts: patients whose disease progressed following an autologous stem cell transplantation and subsequent treatment with brentuximab vedotin, an antibody drug conjugate (Cohort 1); patients who failed salvage chemotherapy and were ineligible for a transplant and whose disease progressed following treatment with","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:47+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\/","name":"KEYTRUDA\u00ae (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-06-06T07:00:00+00:00","dateModified":"2025-11-07T06:25:47+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-shows-overall-response-rates-of-73-to-83-percent-with-complete-response-rates-of-27-to-30-percent-in-heavily-pre-treated-patients-with-chl-in-update-to-study-kn-087\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"KEYTRUDA\u00ae (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"26e816bf-8a95-4fc5-aa4f-dcf67a951439","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/KEYTRUDA-pembrolizumab-Shows-Overall-Response-Rates-of-73-to-83-Percent-with-Complete-Response-Rates-of-27-to-30-Percent-in-Heavily-P-G3V0U.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745369\/revisions"}],"predecessor-version":[{"id":3674765,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745369\/revisions\/3674765"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745369"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}